Powered by

Newron Announces 2017 Financial Results and Provides Outlook for 2018

Mar 01, 2018 - Business Wire

Newron Pharmaceuticals S.p.A. ("Newron"), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announces its financial results and operational highlights for the year ended December 31, 2017, and provides an outlook for 2018. Additionally, Newron announces the approved agenda for the Company's 2018 shareholders' meeting.

Xadago® (safinamide)

Xadago available in the US for the treatmen...